We are glad to share with you about the results of our work, company news, and give you timely developments and personnel appointment and removal conditions.
Zanubrutinib is a novel BTK (Bruton's tyrosine kinase) inhibitor independently developed by BeiGene in China. It belongs to the small-molecule targeted anti-tumor drug category.
Carfilzomib is a targeted anti-tumor drug, belonging to the class of irreversible proteasome inhibitors, primarily used to treat relapsed or refractory multiple myeloma (RRMM).
Upatinib is an orally administered, highly selective JAK1 inhibitor, a small-molecule targeted therapy primarily used to treat various immune-mediated chronic inflammatory diseases.
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies.Privacy Policy
27 2026-04 
27 2026-04 
27 2026-04